TO INNOVATIONS

SATELLITE SESSIONS THURSDAY 27 OCTOBER 2016
SATELLITE SESSIONS
SATELLITE SESSION 3 07:30- 08:45 3 SESSION ROOM 3A
01. THE PRESERVING EFFECTIVE TB TREATMENT STUDY (PETTS):
METHODS, FINAL RESULTS, CONCLUSIONS AND POLICY IMPLICATIONS
Scientific section: Tuberculosis
Organised by: Centers for Disease Control and Prevention (CDC)
Chair: Ruwen Jou (Taiwan)
PETTS was a large prospective cohort study, enrolling 1,761 patients in 9 countries starting in 2005, following them with monthly sputum cultures
to 2010. Thanks to the efforts of over 85 investigators at 26 sites and 17 laboratories in 10 countries, a patient database was established with clinical,
treatment, and laboratory data, a laboratory database with specimen-level results for drug susceptibility testing, genotyping, and DNA sequencing,
and an archive of over 5,500 isolates. The study´s methods and final results to date will be presented and policy implications discussed with active
participation of the audience.
7.30 Goals, study population, methods – Ekaterina Kurbatova (United States of America)
7.50 Main results – Peter Cegielski (United States of America)
8.10 Implications for policy and research – Ernesto Jaramillo (Switzerland)
8.30 Panel discussion, Q & A
8.45 Adjourn
SATELLITE SESSION 3 07:30-08:45 3 SESSION ROOM 3B
02. PUSHING THE BOUNDARIES: USE OF NEW TB DRUGS, THE MSF EXPERIENCE
Scientific section: Tuberculosis
Organised by: Medecins Sans Frontieres (MSF)
Co-Chairs: Philipp du Cros (United Kingdom), Alena Skrahina (Belarus)
With the arrival of two new drugs to treat MDRTB, bedaquiline and delamanid, and subsequent WHO guidance on their use, National tuberculosis
programmes (NTPs) around the world are introducing these drugs into routine programmatic use. Médecins sans frontières (MSF) is supporting NTPs
with this challenge. This satellite aims to share the combined experience of MSF and NTPs from different settings around the world,
in opening up the access to these drugs and expanding their indications and use, including the use of delamanid and bedaquiline in combination,
delamanid in children and extended use beyond 24 weeks of bedaquiline and delamanid.
17.30 Update on MSF projects & global scale up of new & repurposed drugs – Krzysztof Herboczek (United Kingdom)
17.45 Description and preliminary results of patients receiving Dlm in MSF-NTP projects – Catherine Hewison (France)
18.00 Dlm-Bdq combination: Programmatic aspects and preliminary results of patients receiving Dlm and Bdq combination in MSFNTP projects –
Gabriella Ferlazzo (South Africa)
18.15 Extending Bdq or Dlm beyond 24 weeks: description and preliminary results of patients receiving Dlm or Bdq longer than 24 weeks –
Animesh Sinha (Belarus)
18.30 Children and adolescents under Dlm: description and preliminary results of children and adolescents receiving Dlm –
Sylvie Jonckheere (India)
18.45 Discussion
98 CONFRONTING RESISTANCE: FUNDAMENTALS TO INNOVATION - THE 47 TH UNION WORLD CONFERENCE ON LUNG HEALTH